PracticalDermatology

Silicon+ Technology Skincare Line, Good Science Beauty

Good Science Beauty recently launched a line of six collagen-boosting products delivered by Good Silicon+ technology, which is made from natural silicon, lipids, and amino acids. Its honeycomb-like shape holds and protects proven ingredients, delivering them deep within the skin. It slowly dissolves to release ingredients over time. When Good Silicon+ dissolves, it turns into absorbable silicon called orthosilicic acid, which helps stimulate natural collagen production and keeps skin strong. The six-piece Good Science Beauty product range includes: 001-Pu: Purifying Face Cream; 001-Pu: Purifying Face Mask; 002-Re: Skin Renewing Polishing Powder; 003-Hy: Hydrating Face Cream; 004-Br: Skin Brightening Cream; and 005-Fi: Skin Firming Cream. GoodScienceBeauty.com

AccuTite for Face and Body, InMode

InMode Ltd. is introducing AccuTite, the smallest Radio-Frequency Assisted Lipolysis (RFAL) device for precision fat reduction or skin contraction in the face and body. With its sub-millimeter cannula, AccuTite enables focal RF contraction without excisional surgery. There is little or no visible scarring and minimum downtime with AccuTite. The procedure takes less than 15 minutes under local anesthesia. Results can be seen immediately with continuing improvements for several weeks following treatment. These results are maintained for up to 12 months post-RFAL procedure. AccuTite now joins InMode’s RFAL technologies. inmodemd.com

AlphaRet Exfoliating Peel Pads, Skinbetter Science

The AlphaRet Exfoliating Peel Pad from Skinbetter Science has a patented, triple-acid formulation, enhanced with the company’s patented retinoid, AlphaRet, which exfoliates skin, leaving it smooth and bright. The individually packages pads allow for single use in the evening. According to the company, 100 percent of patients experienced noticeable results of healthier, brighter, smoother and more radiant looking skin after three weeks. Skinbetter.com

Comprehensive Men’s Kit, Defanage Skincare

Progenitor Biologics, LLC, the manufacturer and distributor of DefenAge Skincare, has introduced a new Men’s Kit. The fully fragrance-free set takes the guesswork out of results-driven skincare for men using a clearly outlined step-by-step system. The line’s key proprietary ingredient, Age-Repair Defensins reprograms the skin to become visibly younger every day. Comprehensive, dermatologist-driven clinical studies show that the system minimizes visible pores and wrinkles, improves brightness, evenness, oiliness, tone, texture, and hydration in six weeks. DefenAge Men’s Kit offers an easy-to-follow luxurious skincare protocol: a facial cleanser, a daily skin renewing cream and serum, and an exfoliating mask to use once or twice a week. In addition, the Men’s Kit contains a hemp sports towel and is housed in an elegant black leather toiletry bag. Defenage.com

New Line, Kylie Skin

Kylie Jenner’s new skincare lime, Kylie Skin, launched with six products suitable for every skin type. The cruelty-free, gluten-free, sulfate-free, paraben-free and vegan skincare line includes: Eye Cream; Walnut Face Scrub; Vanilla Milk Toner; Face Moisturizer; Foaming Face Wash; and Vitamin C Serum. The bundle, sold for $125, sold out and a re-stock date is pending. KylieSkin.com

New in My Practice Rx: Duobrii

With Lawrence J. Green, MD

In each issue, Practical Dermatology® magazine asks leading skincare physicians about the newest treatments that they are recommending to patients. This month, Lawrence J. Green, MD, a dermatologist in Rockville, MD, talks about Duobrii (halobetasol propionate and tazarotene, Ortho Dermatologics), the first and currently only lotion for adults with plaque psoriasis that contains these two active ingredients.

“Duobrii gives us safety and efficacy—especially long-term safety and efficacy—that we have not seen in a product before. It is a great addition to our ability to treat mild plaque psoriasis for us and our fortunate patients,” he says.

Tell us more about Duobrii.

Lawrence J. Green, MD: Duobrii is the first combination topical product of tazarotene and halobetasol. The idea is to use a medication that has been FDA-approved for psoriasis for years, but known to be irritating when applied to psoriasis plaques (tazarotene) and combine it with an elegant corticosteroid vehicle (halobetasol) to reduce the irritation potential. Combining tazarotene with a topical steroid like halobetasol may decrease the risk of steroid-induced atrophy and provide greater efficacy. The corticosteroid in Duobrii is a halobetasol 0.01% in an elegant vehicle, which is much less than the 0.05% concentration in other available halobetasol products, but it has already been shown to work quite well on its own and is comparable to a class I-II steroid to treat mild chronic plaque psoriasis.

What have the clinical studies shown about Duobrii?

Dr. Green: Phase 3 clinical studies demonstrated rapid onset of action where Duobrii was significantly more effective than its vehicle at two weeks. Study patients continued to improve even more from there for the eight-week study duration. And when the product was stopped after eight weeks, study participants did not have the usual topical steroid loss of response. The improvement achieved was only minimally decreased during the next four weeks. Adverse events and side effects were minimal during the studies, and burning, itching, and stinging were significantly decreased compared with the vehicle. Duobrii was also studied for one year in a long-term safety evaluation. Study participants who did not achieve treatment success after four weeks of continuous therapy were allowed to continue for up to 24 weeks. Even though these subjects applied daily medication for about six months, there were no signals for local or systemic adverse events noted. If a topical steroid alone were used for six months, we would expect cutaneous adverse events, like atrophy.

Which psoriasis patients will benefit most from this new agent?

Dr. Green: I think Duobrii is a first-line medication. It seems to be as effective as any class I steroid cream but without the risks associated with it. We can feel safe that when a patient continues to use it for months, atrophy and telengectasias will not occur. I think most patients with milder plaque psoriasis will benefit from Duobrii whether they have mild plaque psoriasis in general or severe plaque psoriasis that is now mild after biologic therapy. People with thick, stubborn plaques, even if on their palms, should benefit from Duobrii. I would not recommend Duobrii on the face and would be cautious with using it in intertriginous areas. I would not recommend using it on patients with large amounts of psoriasis on their skin. It is not meant to replace a systemic therapy like biologics.

Dr. Green is an advisor and clinical investigator for Ortho Dermatologics, the company that manufactures Duobrii.